RELX-INTERNATIONAL
17.5.2022 15:28:06 CEST | Business Wire | Press release
RELX International, a responsible multinational electronic cigarettes company, is urging decision-makers in Morocco and Algeria to roll out comprehensive regulatory frameworks for e-cigarettes, ahead of an expected surge in smoking habits. Longstanding research has shown that smoking traditional, tobacco-based cigarettes poses significant health risks.
According to data compiled by website GSTHR.org (Global State of Tobacco Harm Reduction), there has been an upward trend in current smoking prevalence in the general population in Morocco.
In 2015, overall prevalence was estimated to be 23%, with a projection to increase to 28% by 2025 in Morocco. [1]. While in Algeria, current smoking trends for the overall adult population is also projected to increase, with an estimate of 16.9% by 2025 as per GSTHR.org. [2].
In contrast to traditional cigarettes, e-cigarettes are increasingly being hailed as a better alternative and can even help adult smokers reduce or quit smoking entirely according to several organisations, including the UK’s National Health Service (NHS). The service has found that e-cigarettes are around 95% less harmful than tobacco and have the potential to help smokers quit entirely [3]. A first of its kind clinical trial conducted by the Queen Mary University of London also found e-cigarettes are almost twice as effective as nicotine replacement treatments, such as patches and gum, at helping smokers to quit [4].
As more governments and health authorities endorse the benefits of e-cigarettes based on scientific testing – and given the expected increase in smoking habits in Morocco and Algeria, authorities should roll out risk-proportionate regulatory frameworks to govern the import, marketing and distribution of e-cigarettes. By doing so, adult smokers in both countries will have access to quality products from brands such as RELX that comply with international and local quality and safety health regulations, are priced accessibly, and are imported and distributed legally, in support of the economy.
Should these markets remain unregulated, it is likely that illicit trade will grow significantly, and see the markets seeded with counterfeit products of questionable quality. These products could pose a significant risk to smokers’ health and could end up in the hands of those under the legal age.
Links:
[1] Smoking, vaping, HTP, NRT and snus in Morocco
[2] Smoking, vaping, HTP, NRT and snus in Algeria
[3] E-cigarettes around 95% less harmful than tobacco estimates landmark review
[4] E-cigarettes more effective than nicotine replacement therapies, finds major UK clinical trial
[5] CBP, FDA Seize Counterfeit, Unauthorized E-Cigarettes
Notes to Editors
RELX International
Founded in 2019, RELX International is a multinational electronic cigarettes company that markets and sells RELX, The World’s Advanced vape brand powered by SuperSmooth™ technology. RELX, Asia’s leading e-cigarette brand, is widening its footprint across the world, and it is currently available in 40+ countries such as the UK, France, Italy, Germany, Indonesia, Philippines, Canada, KSA and the UAE. What sets RELX apart from competition is the fact that it has a full ecosystem (such as closed pods, disposables, device, and power bank accessories) that are designed at a cutting-edge research and development center and produced at one of the world’s largest e-cigarette factories. RELX's mission is to make RELX a trusted brand for legal age adult smokers through state-of-the-art products, industry-leading technologies, and scientific advances in collaboration with talented and committed people around the globe. The company has attracted global talents from Uber, Procter & Gamble, Apple, Beats, and L'Oréal. RELX is proud to be listed in Dubai Duty Free, the first duty free channel in the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516006137/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release
CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla
BMG and Concord Combine to Create World’s Leading Independent Music Company28.4.2026 14:11:00 CEST | Press release
Creates global platform to deliver superior service to artists, songwriters, and partnersUnlocks meaningful value through greater scale and strong cash flow, enabling continued investment in music rights, creative talent, and technologyBob Valentine to serve as CEO and Thomas Coesfeld as Chairman of the combined company, with global headquarters in Nashville and European Headquarters in BerlinCombined company to be named BMG with divisions “BMG Publishing” and “Concord Records” BMG and Concord today announced a definitive agreement to combine their businesses, creating the leading independent music company in the world. Operating under the BMG name, the combined company will bring together two highly complementary businesses to establish a scaled, global company delivering superior service to artists, songwriters, and partners – firmly grounded in an independent, artist-first model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study28.4.2026 14:00:00 CEST | Press release
NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS) study findings were presented from the podium at the Pediatric Academic Society in Boston, MA on Monday, April 27th at 10 am EST by lead author Dr. Heather Siefkes on behalf of colleagues at the University of California, Davis and the University of Mississippi
KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center28.4.2026 11:54:00 CEST | Press release
Delivering up to 130kW of liquid cooling per rack, the solution synchronizes cooling output with IT load in real time within seconds, to support high-density AI, large-scale computing, and HPC deployments, while reducing build time by 70% KAYTUS, a leading provider in AI infrastructure and liquid-cooling solutions, announced that its AI Compute Pod has received both the 2026 iF Design Award and Red Dot Award. This dual recognition not only stems from its outstanding performance in green, low-energy operation—achieving up to 130 kW cooling capacity per rack and a PUE as low as 1.1 through optimized thermal and power design—but also from its innovative approach to intelligent control and efficient O&M. The solution enables second-level synchronization between cooling and IT workloads, and leverages a dual-group control strategy to improve cooling energy efficiency by over 10%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
